BackEZZ Life Science Holdings Limited Overview

EZZ Life Science Holdings Limited Total Assets

Latest total assets for EZZ.AX: $28M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$27.64M
↓ 18.60% YoYΔ $-6.31M vs prior year quarter

Peer trimmed avg / median

Loading

EZZ Life Science Holdings Limited Total Assets History

Loading

EZZ Life Science Holdings Limited vs. peers: Total Assets Comparison

Loading

EZZ Life Science Holdings Limited Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

EZZ Life Science Holdings Limited (EZZ.AX) FAQ

EZZ Life Science Holdings Limited's total assets stands at $28M as of June 2026. That compares with $34M in the prior-year period — down 18.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

EZZ Life Science Holdings Limited reported $28M in total assets versus $34M a year earlier — a 18.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $34M in the prior-year period — down 18.6% year over year. Sustained growth in total assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how EZZ Life Science Holdings Limited's total assets evolved across reporting periods, while the comparison chart places EZZ.AX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total assets is commonly used to spot outliers. EZZ Life Science Holdings Limited's reading of $28M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.